Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Demeter

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent LymphomaMartin Dreyling, Armando Santoro, Luigina Mollica, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
British Journal of Haematology|May 21, 2021
Screening and monitoring of the BTK<sup>C481S</sup> mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapyCsaba Bödör, Lili Kotmayer, Tamás László, et al.
Mycoses|September 5, 2022
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/FungiscopeMaria Ilaria Del Principe, Danila Seidel, Marianna Criscuolo, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
The Journal of Pathology. Clinical Research|November 21, 2023
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiationTamás László, Lili Kotmayer, Viktória Fésüs, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent LymphomaMartin Dreyling, Armando Santoro, Luigina Mollica, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A O'Connor, Muhit Özcan, Eric D Jacobsen, et al.
British Journal of Haematology|May 21, 2021
Screening and monitoring of the BTK<sup>C481S</sup> mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapyCsaba Bödör, Lili Kotmayer, Tamás László, et al.
Mycoses|September 5, 2022
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/FungiscopeMaria Ilaria Del Principe, Danila Seidel, Marianna Criscuolo, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
The Journal of Pathology. Clinical Research|November 21, 2023
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiationTamás László, Lili Kotmayer, Viktória Fésüs, et al.
Pageof 9